• Je něco špatně v tomto záznamu ?

De-Intensification from Basal-Bolus Insulin Therapy to Liraglutide in Type 2 Diabetes: Predictive Value of Mean Glycaemia during Fasting Test

B. Pavlikova, M. Breburdova, M. Krcma, M. Kriz, J. Kasparek, Z. Rusavy

. 2024 ; 14 (5) : . [pub] 20240428

Status neindexováno Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24012906

Grantová podpora
GA UK 442220 Charles University

BACKGROUND: Successful conversion from insulin therapy to glucagon-like peptide 1 receptor agonist (GLP-1RA) with basal insulin in well-controlled patients has already been demonstrated. However, the data concerning individuals with poor glycaemic control are scarce. The aim of this work was to assess the success rate of insulin therapy to liraglutide transition in poorly controlled diabetes in a real-world clinical setting and to define predictors of success. We are the first to present the method of a fasting test as a way to identify the patients at higher risk of failure after treatment de-intensification. METHODS: The retrospective observational study analyzed data of 62 poorly controlled obese diabetic patients on high-dose insulin therapy, who were subjected to a 72 h fasting test during hospitalization and subsequently switched to liraglutide ± basal insulin therapy. During the fasting, all antidiabetic treatment was discontinued. Patients were classified as responders if they remained on GLP-1RA treatment after 12 months. Non-responders restarted the basal-bolus insulin (BBI) regimen. Development of glycated hemoglobin (HbA1c) and body weight in both groups, alongside with parameters associated with the higher risk of return to the BBI regimen, were analyzed. RESULTS: A total of 71% of patients were switched successfully (=responders). Responders had more significant improvement in HbA1c (-6.4 ± 19.7 vs. -3.4 ± 22.9 mmol/mol) and weight loss (-4.6 ± 7.1 vs. -2.5 ± 4.0). Statistically significant difference between groups was found in initial HbA1c (75.6 ± 17.9 vs. 90.5 ± 23.6; p = 0.04), total daily dose of insulin (67.6 ± 36.4 vs. 90.8 ± 32.4; p = 0.02), and mean glycaemia during the fasting test (6.9 ± 1.7 vs. 8.6 ± 2.2 mmol/L; p < 0.01). CONCLUSIONS: This study confirms that therapy de-intensification in poorly controlled patients with a BBI regimen is possible. Higher baseline HbA1c, total daily insulin dose, and mean glucose during fasting test are negative predictive factors of successful therapy de-escalation.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24012906
003      
CZ-PrNML
005      
20240726151440.0
007      
ta
008      
240723s2024 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/life14050568 $2 doi
035    __
$a (PubMed)38792590
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Pavlikova, Barbora $u First Department of Internal Medicine, University Hospital Pilsen, Charles University, Faculty of Medicine in Pilsen, 323 00 Pilsen, Czech Republic $1 https://orcid.org/0000000299171074
245    10
$a De-Intensification from Basal-Bolus Insulin Therapy to Liraglutide in Type 2 Diabetes: Predictive Value of Mean Glycaemia during Fasting Test / $c B. Pavlikova, M. Breburdova, M. Krcma, M. Kriz, J. Kasparek, Z. Rusavy
520    9_
$a BACKGROUND: Successful conversion from insulin therapy to glucagon-like peptide 1 receptor agonist (GLP-1RA) with basal insulin in well-controlled patients has already been demonstrated. However, the data concerning individuals with poor glycaemic control are scarce. The aim of this work was to assess the success rate of insulin therapy to liraglutide transition in poorly controlled diabetes in a real-world clinical setting and to define predictors of success. We are the first to present the method of a fasting test as a way to identify the patients at higher risk of failure after treatment de-intensification. METHODS: The retrospective observational study analyzed data of 62 poorly controlled obese diabetic patients on high-dose insulin therapy, who were subjected to a 72 h fasting test during hospitalization and subsequently switched to liraglutide ± basal insulin therapy. During the fasting, all antidiabetic treatment was discontinued. Patients were classified as responders if they remained on GLP-1RA treatment after 12 months. Non-responders restarted the basal-bolus insulin (BBI) regimen. Development of glycated hemoglobin (HbA1c) and body weight in both groups, alongside with parameters associated with the higher risk of return to the BBI regimen, were analyzed. RESULTS: A total of 71% of patients were switched successfully (=responders). Responders had more significant improvement in HbA1c (-6.4 ± 19.7 vs. -3.4 ± 22.9 mmol/mol) and weight loss (-4.6 ± 7.1 vs. -2.5 ± 4.0). Statistically significant difference between groups was found in initial HbA1c (75.6 ± 17.9 vs. 90.5 ± 23.6; p = 0.04), total daily dose of insulin (67.6 ± 36.4 vs. 90.8 ± 32.4; p = 0.02), and mean glycaemia during the fasting test (6.9 ± 1.7 vs. 8.6 ± 2.2 mmol/L; p < 0.01). CONCLUSIONS: This study confirms that therapy de-intensification in poorly controlled patients with a BBI regimen is possible. Higher baseline HbA1c, total daily insulin dose, and mean glucose during fasting test are negative predictive factors of successful therapy de-escalation.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Breburdova, Martina $u First Department of Internal Medicine, University Hospital Pilsen, Charles University, Faculty of Medicine in Pilsen, 323 00 Pilsen, Czech Republic
700    1_
$a Krcma, Michal $u First Department of Internal Medicine, University Hospital Pilsen, Charles University, Faculty of Medicine in Pilsen, 323 00 Pilsen, Czech Republic $1 https://orcid.org/0000000215642503 $7 mzk2007390690
700    1_
$a Kriz, Miroslav $u First Department of Internal Medicine, University Hospital Pilsen, Charles University, Faculty of Medicine in Pilsen, 323 00 Pilsen, Czech Republic
700    1_
$a Kasparek, Jan $u First Department of Internal Medicine, University Hospital Pilsen, Charles University, Faculty of Medicine in Pilsen, 323 00 Pilsen, Czech Republic
700    1_
$a Rusavy, Zdenek $u First Department of Internal Medicine, University Hospital Pilsen, Charles University, Faculty of Medicine in Pilsen, 323 00 Pilsen, Czech Republic
773    0_
$w MED00186366 $t Life $x 2075-1729 $g Roč. 14, č. 5 (2024)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38792590 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240723 $b ABA008
991    __
$a 20240726151432 $b ABA008
999    __
$a ok $b bmc $g 2125517 $s 1224769
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2024 $b 14 $c 5 $e 20240428 $i 2075-1729 $m Life $n Life (Basel) $x MED00186366
GRA    __
$a GA UK 442220 $p Charles University
LZP    __
$a Pubmed-20240723

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...